USPTO Examiner SHOMER ISAAC - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18957404MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESNovember 2024April 2025Allow510YesNo
18848678BIOACTIVE GRANULAR HYDROGEL SCAFFOLDS AND USE THEREOFSeptember 2024April 2025Allow720YesNo
18762795MANGANESE-DOPED HOLLOW MESOPOROUS SILICA NANOPARTICLES LOADED WITH CURCUMINJuly 2024November 2024Allow510NoNo
18761863MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024October 2024Allow311YesNo
18761882MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024November 2024Allow511YesNo
18676591Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinMay 2024April 2025Abandon1110NoNo
18636721Atomic Scale Topical Composition with Enhanced Interstitial Cellular Uptake for Increased Moisturizing, Fluidity, Antioxidant and Radiation Protection, Antimicrobial Cleansing and Therapeutics for Optimal Dermal Integrity and Homeostasis.April 2024November 2024Allow721YesNo
18583453GREEN SYNTHESIS OF SILVER NANOPARTICLES ENCAPSULATED IN A NANOSTRUCTURED LIPID CARRIERFebruary 2024September 2024Allow711YesNo
18443850ARTESUNATE POWDERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTUREFebruary 2024September 2024Allow711YesNo
18436704COMPOSITION CONTAINING ANTITUMOR DRUG, AND PREPARATION METHOD THEREOF AND USE THEREOFFebruary 2024April 2025Allow1421YesNo
18432899BLOCK COPOLYMERS AND USES THEREOFFebruary 2024May 2025Abandon1510NoNo
18544197COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSEDecember 2023April 2025Abandon1601NoNo
18503327LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINESNovember 2023October 2024Allow1121YesNo
18289200NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOFNovember 2023October 2024Allow1110YesNo
18375788NANO-PARTICLES THAT CONTAIN SYNTHETIC VARIANTS OF GM3 GANGLIOSIDE AS ADJUVANTS IN VACCINESOctober 2023December 2024Allow1510NoNo
18232877Atomic Scale Topical Composition with Enhanced Interstitial Cellular Uptake for Increased Moisturizing, Fluidity, Antioxidant and Radiation Protection, Antimicrobial Cleansing and Therapeutics for Optimal Dermal Integrity and HomeostasisAugust 2023December 2023Allow410YesNo
18343349Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune ResponsesJune 2023March 2025Abandon2130YesNo
18214021Method of Synthesis of a Nanocomposite including Silymarin-loaded Collagen NanoparticlesJune 2023October 2023Allow410YesNo
18338485METHODS OF MAKING LIPID NANOPARTICLESJune 2023February 2025Allow2020NoNo
18196235LIPID NANOPARTICLESMay 2023January 2025Abandon2110NoNo
18297255COMPOUNDS AND COMPOSITIONS FOR DRUG DELIVERYApril 2023February 2025Abandon2241YesNo
18193689METHOD FOR FORMING A NANOMEDICINAL COMPOSITIONMarch 2023January 2025Allow2110NoNo
18193692METHOD FOR TREATING BLASTOCYSTIS INFECTIONMarch 2023August 2024Allow1610YesNo
18191517Structure-Function Relationships in the Development of Immunotherapeutic AgentsMarch 2023June 2025Abandon2701NoNo
18120298NANOFORMULATION OF SPRIOOXINDOLE AND METHODS FOR TREATING HEPATOCELLULAR CARCINOMAMarch 2023November 2023Allow810YesNo
18114434PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNAFebruary 2023December 2024Abandon2110NoNo
18021613AMPHIPHILIC MATERIAL AND APPLICATION THEREOF IN PREPARATION FOR LIPOSOMEFebruary 2023March 2024Allow1320NoNo
18107353SUSTAINED RELEASE PARTICLE FORMULATIONSFebruary 2023June 2025Allow2911YesNo
18100201Semisolid Oral Dispersions Comprising Active AgentsJanuary 2023March 2025Allow2611YesNo
18150399ORAL COMPOSITIONS AND THE PREPARATION METHODS THEREOFJanuary 2023January 2025Allow2410NoNo
17988857Liposomes Useful for Drug DeliveryNovember 2022February 2025Abandon2710NoNo
17959983PLANT MEDIUM INCLUDING AN OXYGEN-ENABLED COMPOSITIONOctober 2022November 2024Abandon2510NoNo
17952593EXOSOME SYSTEMS, PRODUCTS AND METHODSSeptember 2022January 2025Abandon2810NoNo
17941669COMPOSITIONS AND SYSTEMS COMPRISING TRANSFECTION-COMPETENT VESICLES FREE OF ORGANIC-SOLVENTS AND DETERGENTS AND METHODS RELATED THERETOSeptember 2022August 2023Allow1121YesNo
17899933Stabilizing Camptothecin Pharmaceutical CompositionsAugust 2022October 2024Abandon2610NoNo
17873404LIPID COMPOUND AS WELL AS LIPID VECTOR, NUCLEIC ACID LIPID NANOPARTICLE COMPOSITION, AND PHARMACEUTICAL PREPARATION COMPRISING THE SAMEJuly 2022June 2023Allow1111YesNo
17872974FREEZE-DRIED PRODUCT AND GAS-FILLED MICROVESICLES SUSPENSIONJuly 2022March 2023Allow810NoNo
17812946SUSTAINED DRUG DELIVERY IMPLANTJuly 2022October 2024Abandon2710NoNo
17813001LIPOSOMAL FORMULATIONS OF BCL INHIBITORSJuly 2022March 2025Allow3250YesYes
17810064LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINESJune 2022May 2023Allow1120YesNo
17810055LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINESJune 2022December 2023Abandon1720YesYes
17808412BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USEJune 2022July 2024Allow2510NoNo
17847808OXYGEN GAS SUSTAINED RELEASED NANO-EMULSION COMPOSITION AND METHOD FOR PRODUCING THE SAMEJune 2022December 2023Allow1821YesNo
17842876METAL ORGANIC FRAMEWORK/POROUS SILICATE AND/OR ALUMINOSILICATE NANOCARRIER FOR BLASTOCYSTOSIS TREATMENTJune 2022September 2023Allow1521YesNo
17840700CAPE-LOADED TARGETED MICROVESICULAR CANCER DRUG AND METHOD FOR DEVELOPING THE SAMEJune 2022August 2024Allow2620YesNo
17830615PROTEIN-LOADED PLGA NANOSPHERESJune 2022August 2024Allow2750YesNo
17829960DELIVERY OF AGENTS USING METASTABLE LIPOSOMESJune 2022September 2024Allow2711YesNo
17746249TREATMENT OF HIP PAIN WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONSMay 2022September 2023Allow1631YesNo
17740426Core Shell Silica Particles and Uses Thereof As an Anti-Bacterial AgentMay 2022February 2025Allow3320NoNo
17727993METHODS OF IMPROVING THE SOLUBILITY AND BIOAVAILABILITY OF THERAPEUTIC AGENTSApril 2022December 2024Allow3101YesNo
17713679EXOSOME SYSTEMS, PRODUCTS AND METHODSApril 2022April 2024Abandon2441NoNo
17754327Process for preparing nanoparticles in the form of a powder comprising a bio-resorbable polyesterMarch 2022February 2024Allow2240YesNo
17695999COMPOSITIONS FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS AND METHODS OF MAKING SAMEMarch 2022November 2024Abandon3201NoNo
17684805TREATMENT OF HIP PAIN WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONSMarch 2022September 2023Allow1931YesNo
17589554ANTIFUNGAL NANOPARTICLES FOR TARGETED TREATMENT OF FUNGAL INFECTIONSJanuary 2022July 2024Abandon2901NoNo
17581482NANOCOMPLEXES OF POLYANION-MODIFIED PROTEINSJanuary 2022March 2025Abandon3821NoNo
17579832ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMSJanuary 2022September 2024Allow3240YesNo
17574933BIODEGRADABLE MULTILAYER NANOCAPSULES FOR THE DELIVERY OF BIOLOGICALLY ACTIVE AGENTS IN TARGET CELLSJanuary 2022January 2024Allow2410NoNo
17569967COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE AND MAKING THEREOFJanuary 2022January 2025Abandon3711NoNo
17623839SYNERGISTIC COMBINATIONS OF SYNTHETIC LYSINE ANALOGS, DERIVATIVES, MIMETICS, OR PRODRUGS AND PHARMACEUTICAL AGENTS FOR ENHANCED EFFICACYDecember 2021January 2025Abandon3611NoNo
17548173Trans-Tympanic Membrane Delivery Platform and Uses ThereofDecember 2021January 2025Allow3721YesNo
17541325NUCLEIC ACID STABILIZING SOLUTION FOR VACCINES, THERAPY, DIAGNOSTICS, STORAGE, AND TRANSPORTDecember 2021December 2024Allow3621YesNo
17531957MICRO AND NANOPARTICULATE COMPOSITIONS COMPRISING ANTI-MICROBIALLY ACTIVE GROUPSNovember 2021February 2025Allow3820YesNo
17532795Ros-Responsive Liposomes For Specific TargetingNovember 2021June 2024Allow3010YesNo
17531651IDENTIFICATION AND OPTIMIZATION OF CARBON RADICALS ON HYDRATED GRAPHENE OXIDE FOR UBIQUITOUS ANTIBACTERIAL COATINGSNovember 2021January 2024Allow2610NoNo
17610853GAS-FILLED MICROVESICLESNovember 2021March 2023Allow1720NoNo
17611034FREEZE-DRIED PRODUCT AND GAS-FILLED MICROVESICLES SUSPENSIONNovember 2021April 2022Allow510YesNo
17520200LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINESNovember 2021January 2023Allow1421YesNo
17517826DRUG FORMULATIONS FOR CANCER TREATMENTNovember 2021March 2024Abandon2801NoNo
17515593Reduction Of Tooth Staining Derived From Cationic AntimicrobialsNovember 2021October 2023Allow2310NoNo
17513162COMPOSITIONS AND MEDICAL DEVICES COMPRISING ANTI-MICROBIAL PARTICLESOctober 2021April 2024Abandon2910NoNo
17506525NANOLIPOSOME-MICROBUBBLE CONJUGATE INCLUDING DRUG FOR HAIR LOSS TREATMENT ENCAPSULATED IN NANOLIPOSOME AND COMPOSITION FOR ALLEVIATING OR TREATING HAIR LOSS CONTAINING SAMEOctober 2021December 2023Allow2600YesNo
17506490NANOLIPOSOME-MICROBUBBLE CONJUGATE INCLUDING DRUG FOR HAIR LOSS TREATMENT ENCAPSULATED IN NANOLIPOSOME AND COMPOSITION FOR ALLEVIATING OR TREATING HAIR LOSS CONTAINING SAMEOctober 2021March 2024Allow2810NoNo
17499223Halogenated Fullerene Functionalized as a Biocidal and Chemotactic Spermicide to Vaginally Harbor and Neutralize Spermatozoa for Use as a Safe and Effective ContraceptiveOctober 2021February 2022Allow411YesNo
17492784ANTI-MICROBIAL PARTICLES AND METHODS OF USE THEREOFOctober 2021January 2024Abandon2810NoNo
17601032LIPOSOMES ENCAPSULATING ADENOSINEOctober 2021October 2022Allow1320YesNo
17490576SILICA MICROCAPSULES AND METHODS OF PREPARING SAMESeptember 2021May 2025Allow4420YesNo
17477915GUANYLUREA FUNCTIONALIZED PEPTIDES AND PROTEINS FOR THERAPEUTICSSeptember 2021March 2024Allow3011YesNo
17478604Pharmaceutical Composition on the Basis of Stachytarpheta SP., a Process for obtaining the same and its use for Treating VitiligoSeptember 2021June 2024Abandon3330NoNo
17470874NANOSTRUCTURED LIPID CARRIERS AND STABLE EMULSIONS AND USES THEREOFSeptember 2021September 2024Allow3630YesNo
17470163NANOPARTICLES OF INDIRUBIN, DERIVATIVES THEREOF AND METHODS OF MAKING AND USING SAMESeptember 2021May 2024Abandon3201NoNo
17466778METHODS FOR DECREASING INJURIES ASSOCIATED WITH INTRAOPERATIVE HYPOTENSIONSeptember 2021January 2024Allow2910NoNo
17408135MICROPARTICLES AND NANOPARTICLES HAVING NEGATIVE SURFACE CHARGESAugust 2021October 2023Abandon2610NoNo
17391089Oral Care Compositions For Active Agent DeliveryAugust 2021March 2024Allow3110NoNo
17390912SURFACE FUNCTIONALIZED, HOST-GUEST POLYMER NANO-ASSEMBLIES AND METHODS THEREOFJuly 2021October 2024Allow3821NoNo
17384958NANOPARTICLE DELIVERY SYSTEM FOR TARGETED ANTI-OBESITY TREATMENTJuly 2021June 2024Allow3530YesNo
17384214MESOPOROUS SILICA NANOPARTICLES WITH LIPID BILAYER COATING FOR CARGO DELIVERYJuly 2021August 2024Allow3630NoNo
17376837APTAMER BIOCONJUGATE DRUG DELIVERY DEVICEJuly 2021May 2024Abandon3411NoNo
17366846BLOCK COPOLYMERS AND USES THEREOFJuly 2021February 2024Abandon3120NoNo
17363375Water Dissolvable Macrocyclic Lactone Cyclodextrin ComplexesJune 2021December 2021Allow620YesNo
17354514DEVICES, COMPOSITIONS AND RELATED METHODS FOR ACCELERATING AND ENHANCING BONE REPAIRJune 2021February 2025Allow4451YesNo
17346874FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE PARTICLESJune 2021December 2023Allow3020NoNo
17344106HYDROGEL COMPOSITIONS BASED ON POLYSACCHARIDES AND ZWITTERIONIC POLYMERS, AND METHODS FOR THEIR USEJune 2021June 2025Allow4821YesNo
17326067SEDATIVE LACED TOOTHPASTEMay 2021January 2024Allow3220NoNo
17313334LIPOSOME LOADINGMay 2021March 2024Allow3521NoNo
17286537METHODS OF ISOLATING AND USING DESCEMET'S MEMBRANE AND COMPOSITIONS INCLUDING ISOLATED DESCEMET'S MEMBRANEApril 2021April 2025Allow4831YesNo
17233091PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND WITH DOUBLE CORESHELL STRUCTURE AND METHOD FOR MANUFACTURING THE SAMEApril 2021October 2023Abandon3010NoNo
17233153PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND WITH DOUBLE CORESHELL STRUCTURE AND METHOD FOR MANUFACTURING THE SAMEApril 2021October 2023Abandon3010NoNo
17233040PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND WITH DOUBLE CORE-SHELL STRUCTURE AND METHOD FOR MANUFACTURING THE SAMEApril 2021July 2023Allow2710NoNo
17233069PARTICLE AND PHARMACEUTICAL COMPOSITION COMPRISING AN INSOLUBLE CAMPTOTHECIN COMPOUND WITH DOUBLE CORE-SHELL STRUCTURE AND METHOD FOR MANUFACTURING THE SAMEApril 2021July 2023Allow2710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHOMER, ISAAC.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
15
Examiner Affirmed
10
(66.7%)
Examiner Reversed
5
(33.3%)
Reversal Percentile
48.1%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
102
Allowed After Appeal Filing
25
(24.5%)
Not Allowed After Appeal Filing
77
(75.5%)
Filing Benefit Percentile
30.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 24.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SHOMER, ISAAC - Prosecution Strategy Guide

Executive Summary

Examiner SHOMER, ISAAC works in Art Unit 1612 and has examined 1,168 patent applications in our dataset. With an allowance rate of 62.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner SHOMER, ISAAC's allowance rate of 62.5% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SHOMER, ISAAC receive 2.44 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SHOMER, ISAAC is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +35.1% benefit to allowance rate for applications examined by SHOMER, ISAAC. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.1% of applications are subsequently allowed. This success rate is in the 33% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 31.0% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 61.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 77.3% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 64.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.0% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.7% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.